dyne
therapeutics
reports
third
quarter
financial
results
recent
highlights
successful
financings
including
million
initial
public
offering
million
series
b
expected
fund
proof
concept
data
programs
myotonic
dystrophy
type
duchenne
muscular
dystrophy
waltham
globe
newswire
dyne
therapeutics
nasdaq
dyn
muscle
disease
company
focused
advancing
innovative
therapeutics
people
living
genetically
driven
diseases
today
reported
financial
results
third
quarter
recent
business
highlights
made
important
progress
across
business
third
quarter
including
securing
significant
funding
multiple
financings
culminating
ipo
continuing
attract
exceptional
leaders
dyne
expertise
muscle
rare
diseases
generating
preclinical
data
creating
momentum
pipeline
said
joshua
brumm
president
chief
executive
officer
dyne
expect
cash
resources
support
planned
ind
submissions
three
programs
fourth
quarter
fourth
quarter
achieve
data
two
myotonic
dystrophy
type
duchenne
muscular
dystrophy
programs
following
exciting
third
quarter
dyne
well
positioned
pursue
goal
becoming
world
leading
muscle
disease
recent
highlights
september
dyne
completed
ipo
shares
common
stock
including
full
exercise
underwriters
option
purchase
additional
shares
ipo
price
per
share
gross
proceeds
offering
deducting
underwriting
discount
commissions
offering
expenses
million
company
continued
generate
preclinical
data
quarter
myotonic
dystrophy
type
program
importance
transferrin
receptor
highly
expressed
muscle
cells
foundational
dyne
force
platform
approach
developing
modern
oligonucleotide
therapeutics
serious
muscle
diseases
accelerate
work
across
platform
programs
dyne
developed
preclinical
model
expresses
human
receptor
rather
murine
receptor
preclinical
study
utilizing
model
two
doses
force
conjugate
targeting
resulted
significant
reductions
cytoplasmic
wild
type
dmpk
rna
tibialis
anterior
gastrocnemius
heart
diaphragm
muscles
separate
study
patient
cells
single
dose
dyne
force
conjugate
reduced
nuclear
dmpk
foci
approximately
percent
determined
fluorescence
situ
hybridization
analysis
august
dyne
completed
series
b
preferred
stock
financing
raising
gross
proceeds
million
august
dyne
appointed
susanna
high
mba
chief
operating
officer
coo
high
two
decades
experience
leading
corporate
strategy
portfolio
management
business
planning
operations
biotechnology
companies
prior
joining
dyne
recent
position
coo
bluebird
bio
previously
held
roles
increasing
responsibility
alnylam
pharmaceuticals
including
senior
vice
president
strategy
business
integration
july
company
appointed
pediatric
neurologist
francesco
muntoni
frcpch
fmedsci
scientific
advisory
board
muntoni
global
leader
clinical
research
neuromuscular
disease
particular
expertise
clinical
care
clinical
trial
design
drug
development
duchenne
muscular
dystrophy
romesh
subramanian
chief
scientific
officer
reviews
dyne
novel
approach
developing
modern
oligonucleotides
serious
muscle
diseases
tides
europe
oligonucleotide
peptide
therapeutics
presentation
available
demand
registered
attendees
https
subramanian
also
participate
panel
discussion
oligonucleotide
delivery
beyond
liver
targeted
delivery
virtual
conference
wednesday
november
et
third
quarter
financial
results
cash
cash
equivalents
cash
cash
equivalents
million
september
compared
million
december
research
development
r
expenses
r
expenses
million
third
quarter
compared
million
third
quarter
general
administrative
g
expenses
g
expenses
million
third
quarter
compared
million
third
quarter
net
loss
net
loss
million
per
common
share
third
quarter
compared
million
per
common
share
third
quarter
dyne
therapeutics
dyne
therapeutics
building
leading
muscle
disease
company
focused
advancing
innovative
therapeutics
people
living
genetically
driven
diseases
company
utilizes
proprietary
platform
overcome
current
limitations
muscle
tissue
delivery
modern
oligonucleotide
therapeutic
candidates
dyne
developing
broad
portfolio
therapeutics
muscle
diseases
including
lead
programs
myotonic
dystrophy
type
duchenne
muscular
dystrophy
dmd
facioscapulohumeral
muscular
dystrophy
fshd
information
please
visit
follow
us
twitter
linkedin
facebook
statements
press
release
contains
statements
involve
substantial
risks
uncertainties
statements
statements
historical
facts
contained
press
release
including
statements
regarding
dyne
strategy
future
operations
prospects
plans
objectives
management
expected
timeline
submitting
investigational
new
drug
applications
achieving
data
readouts
sufficiency
cash
resources
constitute
statements
within
meaning
private
securities
litigation
reform
act
words
anticipate
believe
continue
could
estimate
expect
intend
may
might
objective
ongoing
plan
predict
project
potential
would
negative
terms
comparable
terminology
intended
identify
statements
although
statements
contain
identifying
words
dyne
may
actually
achieve
plans
intentions
expectations
disclosed
statements
place
undue
reliance
statements
actual
results
events
could
differ
materially
plans
intentions
expectations
disclosed
statements
result
various
important
factors
including
uncertainties
inherent
identification
development
product
candidates
including
conduct
research
activities
initiation
completion
preclinical
studies
clinical
trials
uncertainties
availability
timing
results
preclinical
studies
timing
dyne
ability
submit
obtain
regulatory
approval
investigational
new
drug
applications
whether
results
preclinical
studies
predictive
results
later
preclinical
studies
clinical
trials
dyne
ability
obtain
sufficient
cash
resources
fund
company
foreseeable
unforeseeable
operating
expenses
capital
expenditure
requirements
impact
pandemic
dyne
business
operations
well
risks
uncertainties
identified
dyne
filings
securities
exchange
commission
sec
including
company
recent
form
subsequent
filings
dyne
may
make
sec
addition
statements
included
press
release
represent
dyne
views
date
press
release
dyne
anticipates
subsequent
events
developments
cause
views
change
however
dyne
may
elect
update
statements
point
future
specifically
disclaims
obligation
statements
relied
upon
representing
dyne
views
date
subsequent
date
press
release
contact
dyne
therapeutics
amy
reilly
areilly
dyne
therapeutics
condensed
statement
operations
unaudited
thousands
except
share
per
share
data
three
months
ended
september
nine
months
ended
september
operating
expenses
research
development
general
administrative
total
operating
expenses
loss
operations
expense
income
net
loss
net
loss
per
diluted
common
shares
outstanding
used
net
loss
per
diluted
